Molecular Partners AG ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.97
- Today's High:
- $5.44
- Open Price:
- $5.11
- 52W Low:
- $4.97
- 52W High:
- $7.36
- Prev. Close:
- $5.48
- Volume:
- 15922
Company Statistics
- Market Cap.:
- $190.75 million
- Book Value:
- 6.274
- Revenue TTM:
- $8.53 million
- Operating Margin TTM:
- -711.06%
- Gross Profit TTM:
- $138.85 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -14.3%
- Return on Equity TTM:
- -26.08%
Company Profile
Molecular Partners AG ADR had its IPO on 2021-06-16 under the ticker symbol MOLN.
The company operates in the Healthcare sector and Biotechnology industry. Molecular Partners AG ADR has a staff strength of 168 employees.
Stock update
Shares of Molecular Partners AG ADR opened at $5.11 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.97 - $5.44, and closed at $5.18.
This is a -5.47% slip from the previous day's closing price.
A total volume of 15,922 shares were traded at the close of the day’s session.
In the last one week, shares of Molecular Partners AG ADR have slipped by -13.67%.
Molecular Partners AG ADR's Key Ratios
Molecular Partners AG ADR has a market cap of $190.75 million, indicating a price to book ratio of 0.9451 and a price to sales ratio of 1.3065.
In the last 12-months Molecular Partners AG ADR’s revenue was $8.53 million with a gross profit of $138.85 million and an EBITDA of $-59720000. The EBITDA ratio measures Molecular Partners AG ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Molecular Partners AG ADR’s operating margin was -711.06% while its return on assets stood at -14.3% with a return of equity of -26.08%.
In Q2, Molecular Partners AG ADR’s quarterly earnings growth was a positive 0% while revenue growth was a negative 96.5%.
Molecular Partners AG ADR’s PE and PEG Ratio
- Forward PE
- 1.7775
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.16 per share while it has a forward price to earnings multiple of 1.7775 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Molecular Partners AG ADR’s profitability.
Molecular Partners AG ADR stock is trading at a EV to sales ratio of 11.08 and a EV to EBITDA ratio of -0.3479. Its price to sales ratio in the trailing 12-months stood at 1.3065.
Molecular Partners AG ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $230.49 million
- Total Liabilities
- $15.67 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $182000
- Dividend Payout Ratio
- 0%
Molecular Partners AG ADR ended 2024 with $230.49 million in total assets and $0 in total liabilities. Its intangible assets were valued at $230.49 million while shareholder equity stood at $205.98 million.
Molecular Partners AG ADR ended 2024 with $0 in deferred long-term liabilities, $15.67 million in other current liabilities, 3633000.00 in common stock, $-160056000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $63.24 million and cash and short-term investments were $218.20 million. The company’s total short-term debt was $1,203,000 while long-term debt stood at $0.
Molecular Partners AG ADR’s total current assets stands at $223.86 million while long-term investments were $0 and short-term investments were $154.95 million. Its net receivables were $1.51 million compared to accounts payable of $2.74 million and inventory worth $0.
In 2024, Molecular Partners AG ADR's operating cash flow was $0 while its capital expenditure stood at $182000.
Comparatively, Molecular Partners AG ADR paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.18
- 52-Week High
- $7.36
- 52-Week Low
- $4.97
- Analyst Target Price
- $10.13
Molecular Partners AG ADR stock is currently trading at $5.18 per share. It touched a 52-week high of $7.36 and a 52-week low of $7.36. Analysts tracking the stock have a 12-month average target price of $10.13.
Its 50-day moving average was $6.11 and 200-day moving average was $6.39 The short ratio stood at 1.95 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 259.4% are held by institutions.
Frequently Asked Questions About Molecular Partners AG ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops ankyrin proteins for the treatment of oncology and virology diseases. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration, as well as for diabetic macular edema; and ensovibep (MP0420), a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, a DARPin molecule, which activates T-cells and other immune cells; MP0317, that allows tumor-restricted immune-cell CD40 activation for the treatment of fibroblast activation protein (FAP) positive cancers, which is in Phase I clinical trials; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274, that uses HER2-specific DARPin binding proteins. It also develops MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor (VEGF)and hepatocyte growth factor. Molecular Partners AG has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.